UNITED STATES INTERNATIONAL TRADE COMMISSION
WASHINGTON, D.C. 20436

In the Matter of
CERTAIN SLEEP-DISORDERED BREATHING TREATMENT SYSTEMS AND COMPONENTS THEREOF

Investigation No. 337-TA-____

COMPLAINT OF RESMED LTD, RESMED INC., AND RESMED CORP. UNDER SECTION 337 OF THE TARIFF ACT OF 1930, AS AMENDED

COMPLAINANTS
ResMed Corp
9001 Spectrum Center Drive
San Diego, CA 92123
USA
Telephone: (858)-836-5000

ResMed Inc.
9001 Spectrum Center Drive
San Diego, CA 92123
USA
Telephone: (858)-836-5000

ResMed Ltd
1 Elizabeth Macarthur Drive
Bella Vista NSW 2153
Australia
Telephone: +61 (2) 8884 1000

PROPOSED RESPONDENTS
Apex Medical Corp.
No. 9, Min Sheng St.
Tu-Cheng, New Taipei City, 23679
Taiwan
Telephone: +886-22685568

Apex Medical USA Corp.
615 N. Berry St. Suite D
Brea, CA 92821,
USA
Telephone: (714)-671-3818

Medical Depot Inc., d/b/a Drive Medical Design & Manufacturing
99 Seaview Blvd Ste 210
Port Washington, NY 11050
USA
Telephone: (516)-998-4600

COUNSEL FOR COMPLAINANT
Roger Denning
Scott Penner
FISH & RICHARDSON P.C.
12390 El Camino Real
San Diego, CA 92130
Telephone: (858)-678-5070
Fax: (858)-678-5099
Thomas "Monty" Fusco  
W. Peter Guarnieri  
FISH & RICHARDSON P.C.  
1425 K Street, N.W., 11th Floor  
Washington, D.C. 20005  
Telephone: (202) 783-5070  
Fax: (202) 783-2331

Frank E. Scherkenbach  
FISH & RICHARDSON P.C.  
One Marina Park Drive  
Boston, MA 02210-1878  
Telephone: (617)-542-5070  
Fax: (617)-542-8906

Michael J. Kane  
FISH & RICHARDSON P.C.  
3200 RBC Plaza  
60 South Sixth Street  
Minneapolis, MN 55402  
Telephone: (612)-335-5070  
Fax: (612)-288-9696
# TABLE OF CONTENTS

I. INTRODUCTION ........................................................................................................... 11

II. COMPLAINANTS ....................................................................................................... 13

III. PROPOSED RESPONDENTS ................................................................................... 15

IV. PRODUCTS AND TECHNOLOGY AT ISSUE ............................................................. 16

V. THE ASSERTED PATENTS ........................................................................................ 18
   A. U.S. Patent No. 7,159,587 ...................................................................................... 21
      1. Identification of the Patent and Ownership by ResMed ........................................ 21
      2. Non-Technical Description of the Patented Invention .......................................... 22
      3. Foreign Counterparts to the '587 Patent .............................................................. 22
      1. Identification of the Patents and Ownership by ResMed ....................................... 22
      2. Non-Technical Description of the Patented Invention .......................................... 23
      3. Foreign Counterparts to the '772 Patent .............................................................. 24
      4. Foreign Counterparts to the '267 Patent .............................................................. 25
   C. U.S. Patent No. 7,743,767 ...................................................................................... 25
      1. Identification of the Patents and Ownership by ResMed ....................................... 25
      2. Non-Technical Description of the Patented Invention .......................................... 25
      3. Foreign Counterparts to the '767 Patent .............................................................. 26
   D. U.S. Patent No. 6,216,691 ...................................................................................... 26
      1. Identification of the Patent and Ownership by ResMed ....................................... 27
      2. Non-Technical Description of the Patented Invention .......................................... 27
      3. Foreign Counterparts to the '691 Patent .............................................................. 28
   E. U.S. Patent Nos. 6,935,337 and 7,614,398 ............................................................. 28
      1. Identification of the Patents and Ownership by ResMed ....................................... 28
      2. Non-Technical Description of the Patented Invention .......................................... 29
      3. Foreign Counterparts to the '337 Patent .............................................................. 31
      4. Foreign Counterparts to the '398 Patent .............................................................. 31

VI. THE DOMESTIC INDUSTRY .................................................................................... 31

VII. UNLAWFUL AND UNFAIR ACTS OF PROPOSED RESPONDENTS ............. 35
   A. Apex ....................................................................................................................... 35
   B. Drive ..................................................................................................................... 38

VIII. SPECIFIC INSTANCES OF UNFAIR IMPORTATION AND SALE ............... 40
<table>
<thead>
<tr>
<th>Exhibit Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Copy of U.S. Patent No. 7,159,587</td>
</tr>
<tr>
<td>2</td>
<td>Certified Copy of U.S. Patent No. 7,487,772</td>
</tr>
<tr>
<td>3</td>
<td>Certified Copy of U.S. Patent No. 7,997,267</td>
</tr>
<tr>
<td>4</td>
<td>Certified Copy of U.S. Patent No. 7,743,767</td>
</tr>
<tr>
<td>5</td>
<td>Certified Copy of U.S. Patent No. 6,216,691</td>
</tr>
<tr>
<td>6</td>
<td>Certified Copy of U.S. Patent No. 6,935,337</td>
</tr>
<tr>
<td>7</td>
<td>Certified Copy of U.S. Patent No. 7,614,398</td>
</tr>
<tr>
<td>8</td>
<td>Certified Assignment Documents for U.S. Patent No. 7,159,587</td>
</tr>
<tr>
<td>9</td>
<td>Certified Assignment Documents for U.S. Patent No. 7,487,772</td>
</tr>
<tr>
<td>10</td>
<td>Certified Assignment Documents for U.S. Patent No. 7,997,267</td>
</tr>
<tr>
<td>11</td>
<td>Certified Assignment Documents for U.S. Patent No. 7,743,767</td>
</tr>
<tr>
<td>12</td>
<td>Certified Assignment Documents for U.S. Patent No. 6,216,691</td>
</tr>
<tr>
<td>13</td>
<td>Certified Assignment Documents for U.S. Patent No. 6,935,337</td>
</tr>
<tr>
<td>14</td>
<td>Certified Assignment Documents for U.S. Patent No. 7,614,398</td>
</tr>
<tr>
<td>15</td>
<td>A List of All Foreign Patents and All Foreign Patent Applications Corresponding to U.S. Patent No. 7,743,767</td>
</tr>
<tr>
<td>16</td>
<td>A List of All Foreign Patents and All Foreign Patent Applications Corresponding to U.S. Patent No. 7,159,587</td>
</tr>
<tr>
<td>17</td>
<td>A List of All Foreign Patents and All Foreign Patent Applications Corresponding to U.S. Patent No. 7,487,772</td>
</tr>
<tr>
<td>18</td>
<td>A List of All Foreign Patents and All Foreign Patent Applications Corresponding to U.S. Patent No. 7,743,767</td>
</tr>
<tr>
<td>19</td>
<td>A List of All Foreign Patents and All Foreign Patent Applications Corresponding to U.S. Patent No. 6,216,691</td>
</tr>
<tr>
<td>20</td>
<td>A List of All Foreign Patents and All Foreign Patent Applications Corresponding to U.S. Patent No. 6,935,337</td>
</tr>
<tr>
<td>21</td>
<td>A List of All Foreign Patents and All Foreign Patent Applications Corresponding to U.S. Patent No. 7,614,398</td>
</tr>
<tr>
<td>22</td>
<td>Photographs of the ResMed Mirage Activa LT</td>
</tr>
<tr>
<td>23</td>
<td>Photographs of the ResMed Liberty</td>
</tr>
<tr>
<td>24</td>
<td>Photographs of the ResMed Mirage Micro</td>
</tr>
<tr>
<td>25</td>
<td>Photographs of the ResMed Mirage Quattro</td>
</tr>
<tr>
<td>26</td>
<td>Photograph of the ResMed Mirage Vista</td>
</tr>
<tr>
<td>27</td>
<td>Photographs of the ResMed Quattro FX and Quattro FX For Her</td>
</tr>
<tr>
<td>28</td>
<td>Photographs of the ResMed S9 Autoset and HSi</td>
</tr>
<tr>
<td>Exhibit Number</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>29</td>
<td>User Manuals for the ResMed Mirage Activa LT</td>
</tr>
<tr>
<td>30</td>
<td>User Manuals for the ResMed Mirage Liberty</td>
</tr>
<tr>
<td>31</td>
<td>User Manuals for the ResMed Mirage Micro</td>
</tr>
<tr>
<td>32</td>
<td>User Manuals for the ResMed Mirage Quattro</td>
</tr>
<tr>
<td>33</td>
<td>User Manuals for the ResMed Mirage Vista</td>
</tr>
<tr>
<td>34</td>
<td>User Manuals for the ResMed Quattro FX and Quattro FX For Her</td>
</tr>
<tr>
<td>35</td>
<td>User Manuals for the ResMed S9 Autoset and H5i</td>
</tr>
<tr>
<td>36</td>
<td>RESERVED</td>
</tr>
<tr>
<td>37</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘587 patent to the ResMed Mirage Quattro</td>
</tr>
<tr>
<td>38</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘587 patent to the ResMed Quattro FX and Quattro FX For Her</td>
</tr>
<tr>
<td>39</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘772 patent to the ResMed Mirage Activa LT</td>
</tr>
<tr>
<td>40</td>
<td>RESERVED</td>
</tr>
<tr>
<td>41</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘772 patent to the ResMed Mirage Micro</td>
</tr>
<tr>
<td>42</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘772 patent to the ResMed Mirage Quattro</td>
</tr>
<tr>
<td>43</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘772 patent to the ResMed Mirage Vista</td>
</tr>
<tr>
<td>44</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘772 patent to the ResMed Quattro FX and Quattro FX For Her</td>
</tr>
<tr>
<td>45</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘267 patent to the ResMed Mirage Activa LT</td>
</tr>
<tr>
<td>46</td>
<td>RESERVED</td>
</tr>
<tr>
<td>47</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘267 patent to the ResMed Mirage Micro</td>
</tr>
<tr>
<td>48</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘267 patent to the ResMed Mirage Quattro</td>
</tr>
<tr>
<td>49</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘267 patent to the ResMed Mirage Vista</td>
</tr>
<tr>
<td>50</td>
<td>Exemplary Claim Chart Comparing the Claims of the ‘267 patent to the ResMed Quattro FX and Quattro FX For Her</td>
</tr>
<tr>
<td>Exhibit Number</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>51</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’767 patent to the ResMed Mirage Vista</td>
</tr>
<tr>
<td>52</td>
<td>RESERVED</td>
</tr>
<tr>
<td>53</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’691 patent to the ResMed S9 Autoset</td>
</tr>
<tr>
<td>54</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’337 patent to the ResMed HSi heated humidifier.</td>
</tr>
<tr>
<td>55</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’398 patent to the ResMed HSi heated humidifier.</td>
</tr>
<tr>
<td>56</td>
<td>CONFIDENTIAL EXHIBIT: Declaration of Ben Cheah</td>
</tr>
<tr>
<td>57</td>
<td>Photographs of the Apex WiZARD 210</td>
</tr>
<tr>
<td>58</td>
<td>Photographs of the Apex’s WiZARD 220</td>
</tr>
<tr>
<td>59</td>
<td>Photographs of the Apex XT-Fit</td>
</tr>
<tr>
<td>60</td>
<td>Photographs of the Apex XT Humidifier</td>
</tr>
<tr>
<td>61</td>
<td>Photographs of the Apex iCH Auto</td>
</tr>
<tr>
<td>62</td>
<td>User Brochure for the Apex WiZARD 210 and Apex WiZARD 220</td>
</tr>
<tr>
<td>63</td>
<td>User Brochure for the Apex iCH Auto</td>
</tr>
<tr>
<td>64</td>
<td>User Brochure for the Apex XT-Fit and XT Humidifier</td>
</tr>
<tr>
<td>65</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’587 patent to the Apex WiZARD 210 and Drive Freedom 210</td>
</tr>
<tr>
<td>66</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’587 patent to the Apex WiZARD 220 and Drive Freedom 220</td>
</tr>
<tr>
<td>67</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’772 patent to the Apex WiZARD 210 and Drive Freedom 210</td>
</tr>
<tr>
<td>68</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’772 patent to the Apex WiZARD 220 and Drive Freedom 220</td>
</tr>
<tr>
<td>69</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’267 patent to the Apex WiZARD 210 and Drive Freedom 210</td>
</tr>
<tr>
<td>70</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’267 patent to the Apex WiZARD 220 and Drive Freedom 220</td>
</tr>
<tr>
<td>71</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’767 patent to the Apex WiZARD 210 and Drive Freedom 210</td>
</tr>
<tr>
<td>72</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’691 patent to the Apex XT-Fit</td>
</tr>
<tr>
<td>73</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’691 patent to the Apex iCH Auto</td>
</tr>
<tr>
<td>74</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’337 patent to the Apex iCH</td>
</tr>
<tr>
<td>Exhibit Number</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>75</td>
<td>Auto</td>
</tr>
<tr>
<td>76</td>
<td>Exemplary Claim Chart Comparing the Claims of the ’398 patent to the Apex XT Humidifier</td>
</tr>
<tr>
<td>77</td>
<td>Photographs of Drive Freedom 210</td>
</tr>
<tr>
<td>78</td>
<td>Photographs of Drive Freedom 220</td>
</tr>
<tr>
<td>79</td>
<td>Photographs of the Product Packaging for the Apex WiZARD 220 and WiZARD 220</td>
</tr>
<tr>
<td>80</td>
<td>ResMed Inc.’s Annual Report and Form 10-K</td>
</tr>
<tr>
<td>81</td>
<td>Drive Medical Catalog Page</td>
</tr>
<tr>
<td>82</td>
<td>Apex import data from <a href="http://www.zepol.com">www.zepol.com</a></td>
</tr>
<tr>
<td>83</td>
<td>Photographs of the Drive Freedom 210 with WiZARD 210 branding.</td>
</tr>
<tr>
<td>84</td>
<td>WiZARD 210 Instruction Manual</td>
</tr>
<tr>
<td>85</td>
<td>WiZARD 220 Instruction Manual</td>
</tr>
<tr>
<td>86</td>
<td>iCH Auto Instruction Manual</td>
</tr>
<tr>
<td>87</td>
<td>XT Fit Instruction Manual</td>
</tr>
<tr>
<td>88</td>
<td>XT Heated Humidifier Instruction Manual</td>
</tr>
<tr>
<td>89</td>
<td>CONFIDENTIAL EXHIBIT: Copies of ResMed Inc. and ResMed Corp. Licenses of Asserted Patents</td>
</tr>
<tr>
<td>90</td>
<td>CONFIDENTIAL EXHIBIT: List of all licensees to the ResMed Asserted Patents</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Physical Exhibit Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>ResMed S9 Flow Generator and H5i Humidifier</td>
</tr>
<tr>
<td>P2</td>
<td>ResMed Mirage Quattro Full Face Mask</td>
</tr>
<tr>
<td>P3</td>
<td>Apex WiZARD 210 Nasal Mask with Headgear</td>
</tr>
<tr>
<td>P4</td>
<td>Apex WiZARD 220 Full Face Mask with Headgear</td>
</tr>
<tr>
<td>P5</td>
<td>Apex XT Series Continuous Positive Airway Pressure</td>
</tr>
<tr>
<td>Physical Exhibit Number</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>P6</td>
<td>APEX iCH CPAP Series</td>
</tr>
<tr>
<td>P7</td>
<td>Drive Freedom 210 nasal CPAP mask with small, medium &amp; large cushions</td>
</tr>
</tbody>
</table>
# LIST OF APPENDICES

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Certified Copy of the File History for U.S. Patent No. 7,159,587</td>
</tr>
<tr>
<td>B</td>
<td>Certified Copy of the File History for U.S. Patent No. 7,487,772</td>
</tr>
<tr>
<td>C</td>
<td>Certified Copy of the File History for U.S. Patent No. 7,997,267</td>
</tr>
<tr>
<td>D</td>
<td>Certified Copy of the File History for U.S. Patent No. 7,743,767</td>
</tr>
<tr>
<td>E</td>
<td>Copy of the File History for U.S. Patent No. 6,216,691</td>
</tr>
<tr>
<td>F</td>
<td>Certified Copy of the File History for U.S. Patent No. 6,935,337</td>
</tr>
<tr>
<td>G</td>
<td>Certified Copy of the File History for U.S. Patent No. 7,614,398</td>
</tr>
<tr>
<td>H</td>
<td>Relevant Technical References Cited in U.S. Patent No. 7,159,587</td>
</tr>
<tr>
<td>I</td>
<td>Relevant Technical References Cited in U.S. Patent No. 7,487,772</td>
</tr>
<tr>
<td>J</td>
<td>Relevant Technical References Cited in U.S. Patent No. 7,997,267</td>
</tr>
<tr>
<td>K</td>
<td>Relevant Technical References Cited in U.S. Patent No. 7,743,767</td>
</tr>
<tr>
<td>L</td>
<td>Relevant Technical References Cited in U.S. Patent No. 6,216,691</td>
</tr>
<tr>
<td>M</td>
<td>Relevant Technical References Cited in U.S. Patent No. 6,935,337</td>
</tr>
<tr>
<td>N</td>
<td>Relevant Technical References Cited in U.S. Patent No. 7,614,398</td>
</tr>
</tbody>
</table>
I. INTRODUCTION

1.1 ResMed Corp., ResMed Inc., and ResMed Ltd (sometimes collectively referred to as “ResMed” or “Complainants”) request that the United States International Trade Commission commence an investigation pursuant to Section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. § 1337 (“Section 337”), to remedy the unlawful importation into the United States, sale for importation into the United States, and/or sale within the United States after importation by the owner, importer, or consignee, of certain sleep-disordered breathing treatment systems and components thereof (collectively referred to as “the accused products”), that infringe valid and enforceable United States patents owned by ResMed Ltd, and licensed to ResMed Inc. and ResMed Corp.

ResMed Patents’). The ResMed Patents are valid and enforceable United States Patents, the entire right, title, and interest in and to which ResMed Ltd owns by assignment.

1.3 ResMed asserts that the accused products infringe claims 1, 5, 6, 11, 12, 18, 19, 20, 35 and 36 of the ’772 patent; claims 17, 21, 22, 23, 24, 29, 32, 33, 34, 35, 36, and 37 of the ’267 patent; claim 15 of the ’587 patent; claims 59, 60, 63, 72, 73, 74, and 75 of the ’767 patent; claims 1, 2, 4, 5, 17 and 28 of the ’691 patent; claims 1 and 20 of the ’337 patent; and claims 1, 2, 3, 4, 5, 6 and 7 of the ’398 patent; (collectively, “the asserted claims”). In summary, Proposed Respondents infringe at least the patents and claims listed in the chart below (dependent claims are contained in parentheses).

<table>
<thead>
<tr>
<th>U.S Patent No.</th>
<th>Asserted Claims</th>
</tr>
</thead>
<tbody>
<tr>
<td>’587 patent</td>
<td>15</td>
</tr>
<tr>
<td>’772 patent</td>
<td>1 (5, 6, 11); 12; 18 (19-20); 35; 36</td>
</tr>
<tr>
<td>’267 patent</td>
<td>17; 21 (22, 23, 24, 29); 32 (33, 34, 35, 36, 37)</td>
</tr>
<tr>
<td>’767 patent</td>
<td>59 (60, 63, 72, 73, 74, 75)</td>
</tr>
<tr>
<td>’691 patent</td>
<td>1 (2, 4, 5, 17); 28</td>
</tr>
<tr>
<td>’337 patent</td>
<td>1; 20</td>
</tr>
<tr>
<td>’398 patent</td>
<td>1 (2, 3, 4, 5, 6, 7)</td>
</tr>
</tbody>
</table>

1.4 Proposed Respondents’ activities with respect to the importation into the United States, the sale for importation into the United States, and/or the sale within the United States after importation of certain sleep-disordered breathing treatment systems and components thereof, described more fully, infra, are unlawful under 19 U.S.C. § 1337(a)(1)(B)(i), in that these systems are protected by one or more claims of the valid and enforceable ResMed Patents.
1.5 Certified copies of the Asserted Patents accompany this Complaint as Exhibits 1-7 respectively. ResMed Ltd owns by assignment the entire right, title, and interest in and to these patents. A certified copy of each of the recorded assignments accompanies this Complaint as Exhibits 8-14. Each of the Asserted Patents is licensed to ResMed Inc. and sublicensed to ResMed Corp.

1.6 As required by Section 337(a)(2) and defined in Section 337(a)(3), an industry in the United States exists relating to articles protected by the Asserted Patents.

1.7 ResMed seeks relief from the Commission in the form of a permanent exclusion order, pursuant to Section 337(d), excluding from entry into the United States Proposed Respondents’ accused products that infringe one or more claims of the Asserted Patents. ResMed also seeks a permanent cease and desist order, pursuant to Section 337(f), halting the importation, sale, offer for sale, marketing, advertising, or soliciting of sleep-disordered breathing treatment systems and components thereof by Proposed Respondents and their related companies that infringe ResMed’s valid and enforceable United States patents.

II. COMPLAINANTS

2.1 Complainant ResMed Ltd is a corporation organized under the laws of Australia, having its principal place of business in Bella Vista, New South Wales, Australia. ResMed Ltd owns the patents at issue in this complaint. Complainant ResMed Corp. is a corporation organized under the laws of the state of Minnesota with its principal place of business in San Diego, California. Complainant ResMed Inc. is a corporation organized under the laws of the state of Delaware with its principal place of business in San Diego, California. ResMed Ltd

---

1 ResMed notes that Exhibit I is an un-certified copy of the '587 patent. At the time of filing of the complaint, a certified copy of the '587 patent had been ordered. In accordance with Rule 210(a)(9)(i), a certified copy of the '587 patent will be filed with the Commission when received by Complainants.
licenses the patents at issue to ResMed Inc. which in turn licenses them to ResMed Corp. The Complainants are sometimes collectively referred to as “ResMed” herein. ResMed Corp. and ResMed Ltd are, respectively, direct and indirect subsidiaries of ResMed Inc.

2.2 ResMed is a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing (sometimes referred to as “SDB”). Since its founding in 1989, ResMed has focused on developing and commercializing systems for the treatment of obstructive sleep apnea (“OSA”), a major subset of SDB. ResMed’s development of innovative therapies for the treatment of OSA has resulted in over 3,000 patents granted or pending worldwide, and its product line incorporates technology that is a highly effective and proven way to treat OSA.

2.3 ResMed was originally founded in Australia, but is now a U.S. corporation with its parent, ResMed Inc., incorporated in Delaware and headquartered in San Diego. ResMed Ltd is principally responsible for ResMed’s research and manufacturing operations, which are located in various places around the world. ResMed Inc.’s principal Americas sales subsidiary, ResMed Corp., is co-located in San Diego with the parent company. ResMed Motor Technologies is a wholly owned subsidiary of ResMed Inc., and is responsible for research, development and manufacturing of the motors that are used in ResMed’s flow generators - the principal device used in the SDB systems that ResMed Ltd makes and ResMed Corp. sells.

2.4 ResMed Ltd has invested hundreds of millions of dollars in research and development. It has been estimated that SDB in general, and OSA in particular, affects
approximately 20% of the adult population, making it as widespread as diabetes or asthma. However, awareness of OSA is relatively low; one study in 2002 concluded that about 90% of people with OSA remain undiagnosed and untreated. Therefore, ResMed Corp., in particular, has made substantial investments directed to increasing education and awareness of the health consequences of untreated SDB among both the general public and physicians.

III. PROPOSED RESPONDENTS

3.1 On information and belief, proposed Respondent Apex Medical Corp. ("Apex Medical") is a corporation organized under the laws of the country of Taiwan with its principal place of business at No. 9, Min Sheng St., Tu-Cheng, New Taipei City, 23679, Taiwan. On information and belief, proposed Respondent Apex Medical USA Corp. ("Apex Medical USA") is the U.S. subsidiary of Apex Medical Corp. (collectively, "Apex"); Apex Medical USA Corp. is a corporation organized under the laws of the state of California with its principal place of business at 615 North Berry St, Suite D, Brea, CA 92821, USA.

3.2 As detailed below, on information and belief, Apex is a manufacturer and distributor of durable medical equipment, including systems and components thereof for the treatment of sleep-disordered breathing, such as obstructive sleep apnea.

3.3 Apex develops, manufactures, and markets sleep-disordered breathing treatment systems and components thereof that infringe one or more claims of the Asserted Patents. On information and belief, Apex’s sleep-disordered breathing treatment systems and components thereof are manufactured, assembled, packaged, and/or tested outside of the United States. On information and belief, Apex and/or others then import the accused sleep-disordered breathing treatment systems, and components thereof into the United States, sell them for importation, or sell them in the United States after importation.
3.4 On information and belief, proposed Respondent Medical Depot Inc., d/b/a Drive Medical Design & Manufacturing ("Drive") is a corporation organized under the laws of the state of Delaware with its principal place of business at 99 Seaview Blvd, Ste 210, Port Washington, NY 11050, USA.

3.5 Drive is an importer and seller of durable medical equipment such as sleep-disordered breathing treatment systems and components thereof. Drive markets and sells these products in the United States. As set forth in more detail below, upon information and belief, Drive obtains sleep-disordered breathing treatment systems and components thereof from Apex, imports these systems and/or components into the United States, and sells these systems and/or components in the United States after importation.

IV. PRODUCTS AND TECHNOLOGY AT ISSUE

4.1 The products at issue are medical systems used in the treatment of sleep-disordered breathing ("SDB"), particularly obstructive sleep apnea ("OSA"). As the name implies, a person with OSA will experience obstructed breathing while sleeping as throat muscles relax and close off the breathing passage. After a period as long as ten seconds, the person will reopen the breathing passage by expelling air, only to have the passage close again as the throat muscles relax again, a cycle which may repeat itself several hundred times in the course of a night. The disrupted sleep pattern that results from having OSA not only causes the person to feel unrested after sleeping, but can cause a drop in blood oxygen levels, placing a strain on the person's overall respiratory and circulatory systems.

4.2 In the 1980's, Professor Colin Sullivan at Royal Prince Alfred Hospital in Sydney, Australia and Dr. George Gregory at the University of California, San Francisco began devising methods of treating OSA through the use of continuous positive airway pressure, or "CPAP." CPAP therapy involves the use of mild air pressure to keep the patient's airway open
during sleep. A CPAP therapy system consists of three main elements working together: 1) a flow generator for creating the flow of air, 2) a conduit, usually a flexible tube, for carrying the flow of air to the patient, and 3) an interface (usually a facial mask or a pair of “nasal pillows” that are inserted into the nasal cavities) that provides a connection to the patient’s airway. The continuous flow of air prevents the airway from collapsing during sleep and thus disrupts the OSA cycle described above, leading the patient to a good night's sleep uninterrupted by apneas.

![ResMed CPAP Machine in Use](image)

4.3 The success of CPAP therapy in the treatment of OSA has been widely recognized. Indeed, the University of Maryland Medical Center describes CPAP as the “first-line treatment for mild-to-moderate or severe obstructive sleep apnea.”

4.4 The mask (or pair of nasal pillows) is a critical element of any CPAP therapy system. The mask must maintain an effective seal against the patient’s face since air leakage can significantly reduce the therapeutic effects of the CPAP system. At the same time, if the mask is uncomfortable or constricting, the patient may find the system difficult to use and cease using the system altogether. Indeed, patient noncompliance with therapy because of mask discomfort is a

major concern in the administration of CPAP therapy. This was pointed out in a study published in the journal *Sleep Science* in which it was reported that the most common side effects of CPAP therapy that influence adherence to the treatment are related to nasal complaints, masks, and pressures.³

4.5 ResMed offers a range of flow generators and masks designed to maximize the efficacy of the CPAP therapy delivered. A complete depiction of ResMed’s products, designed to treat OSA in a myriad of patient types across the population, can be found at http://www.resmed.com/products.

4.6 The accused Apex masks are sold under the brand name “WiZARD”. The WiZARD 210 mask is intended to cover only the nose, while the WiZARD 220 mask covers more of the face and is commonly referred to as a “full face” mask. Upon information and belief, Drive imports Apex masks and sells them under its own brand name but with the same numerical designation of the corresponding Apex masks – the Drive products are the Freedom 210 nasal mask and Freedom 220 full face mask. Upon information and belief, Apex has recently begun selling the accused products in the US directly to durable medical equipment providers, as well as selling through Drive.

V. THE ASSERTED PATENTS

5.1 At issue in this investigation is Proposed Respondents’ infringement of seven United States patents: the ’587, ’772, ’767, ’267, ’691, ’337, and ’398 patents. ResMed summarizes the general technology of all the inventions as well as each patent below.

A. General Background

5.2 As noted previously, sleep-disordered breathing ("SDB"), particularly obstructive sleep apnea ("OSA"), can lead to serious and harmful effects on a person’s overall respiratory and circulatory systems. One manner of treating these disorders is through the use of Continuous Positive Airway Pressure ("CPAP") treatments. During CPAP treatment air is continually supplied into a patient’s airways at pressures above the ambient atmospheric pressure while the patient sleeps. This higher pressure air helps keep the patient’s airways open, thereby ensuring a steady supply of oxygen and helping a patient achieve a more restful and healthy sleep. Various different types of CPAP treatment may involve different cycles or levels of pressure during the course of a single treatment (i.e. over the course of single sleeping period). The air is supplied by an air flow generator, through an air conduit, and into a patient interface that generally consists of a mask. Other examples of patient interfaces include a full face mask and nasal prongs or pillows.

5.3 The innovative construction and design of masks used to deliver air during CPAP and related treatments are one subject of the patents-in-suit. The masks generally consist of a mask shell attached to a conduit of some kind, with for example an elbow joint:
5.4 The mask shell includes a cushion or padding so that it rests comfortably on a patient’s face when in contact with the patient’s nose and mouth. The mask may be secured onto a patient’s head with a harness consisting of straps. It may also include other support structures, such as a forehead pad to comfortably brace the mask against the patient’s forehead. The mask will also generally include a vent for exhaling exhaust gas when a patient breathes out; this vent will usually be located on or near the mask shell itself.

5.5 As previously noted, air is provided to the patient by a flow generator. The flow generator generally uses an electric motor driving a fan or turbine to create the high pressure air that is supplied to the mask. ResMed’s patented inventions involve an innovative housing and mounting body for the flow generator. This mounting body helps to minimize the noise produced by the generator while still being economic to manufacture and service. Additionally, because some patients prefer to use humidified air during CPAP treatment, ResMed’s patented inventions also involve the design of humidifiers to humidify the air supplied to the mask.
5.6 Descriptions of the patents asserted in this complaint are set forth in the remainder of this section. The contents of this Complaint, including the subsections entitled “Non-Technical Description of the Patented Invention”, does not, and is not intended to, construe either the specification or claims of the patents asserted herein.

A. U.S. Patent No. 7,159,587

1. Identification of the Patent and Ownership by ResMed


5.8 The inventors of the ’587 patent, Joanne Drew, Alexander Virr, and Geoffrey Crumblin, assigned to ResMed Ltd all rights, title, and interest in the invention ultimately disclosed and claimed in the ’587 patent. See Exhibit 8. The ’587 patent is valid, enforceable, and is currently in full force and effect. A copy of the ’587 patent is attached as Exhibit 1.\(^4\)

5.9 Pursuant to Rule 210.12(c) of the Commission's Rules of Practice and Procedure, this Complaint is accompanied by Appendices A and H. Appendix A contains a certified copy and three additional copies of the prosecution history of the ’587 patent. Appendix H contains four copies of each reference mentioned in that prosecution history.

\(^4\) At the time of filing of the complaint, a certified copy of the ’587 patent had been ordered. In accordance with Rule 210(a)(9)(i), a certified copy of the ’587 patent will be filed with the Commission when received by Complainants.
2. Non-Technical Description of the Patented Invention

5.10 The '587 patent generally discloses a vent assembly for use with a respiratory mask of the type used in a CPAP machine. *See* Exhibit 1, '587 Patent at Abstract. Figure 1 of the '587 patent depicts one embodiment of this vent assembly included on a respiratory mask:

![Diagram](image)

*See id. at Fig. 1*

5.11 The vent is generally used to eliminate CO₂ by a patient, and is sometimes referred to as a gas washout vent or CO₂ washout vent. *See id.* at col. 1:62-65. The vent can be located in the mask shell (*see id.* at Fig. 1) or in the gas inlet (*see id.* at Fig. 2), and the vent can include a plurality of small holes, designed to allow gas to exit the breathing cavity quietly. *See id.* at col. 1:66 – col. 2:5.

3. Foreign Counterparts to the '587 Patent

5.12 The foreign counterparts to the '587 patent are listed in Exhibit 16. No other foreign patents or patent applications corresponding to the '587 patent have been filed, abandoned, withdrawn or rejected.

B. U.S. Patent Nos. 7,487,772 and 7,997,267

1. Identification of the Patents and Ownership by ResMed

5.14 The inventors of both the '772 and '267 patents, Anthony M. Ging, Saad Nasr, Rachael E. Moore, and Andrew M. Price, assigned to ResMed Ltd all rights, title, and interest in the invention ultimately disclosed and claimed in both the '772 and '267 patents. See Exhibits 9 and 10. The '772 and '267 patents are valid, enforceable, and are currently in full force and effect. A certified copy of the '772 patent is attached as Exhibit 2, and a certified copy of the '267 patent is attached as Exhibit 3.

5.15 Pursuant to Rule 210.12(c) of the Commission's Rules of Practice and Procedure, this Complaint is accompanied by Appendices B, C, I, and J. Appendix B contains a certified copy and three additional copies of the prosecution history of the '772 patent; Appendix I contains four copies of each reference mentioned in that prosecution history. Appendix C contains a certified copy and three additional copies of the prosecution history of the '267 patent; Appendix J contains four copies of each reference mentioned in that prosecution history.

2. Non-Technical Description of the Patented Invention
5.16 The '772 and '267 patents generally disclose a respiratory mask assembly for delivering breathable air to a patient. See Exhibit 2, '772 Patent, at Abstract, and Exhibit 3, '267 patent, at Abstract. An embodiment of the invention is pictured in Figure 1:

![Figure 1]

See id. at Fig. 1

5.17 The frame includes both a front surface, as well as a rear surface adapted to face the patient. See id. at Abstract. A main body of the frame includes an opening for breathable gas to flow through and be introduced into the patient's nasal cavity. See id. The mask assembly also includes an elbow assembly connected to the front surface of the frame by a connector. See id. The elbow assembly is connected to the front surface in a way that allows it to swivel by using a swivel elbow. See id. Additionally, the swivel elbow has an air intake port and can have an air exhaust port, the two ports separated by a baffle. See id.

3. Foreign Counterparts to the '772 Patent

5.18 The foreign counterparts to the '772 patent are listed in Exhibit 17. No other foreign patents or patent applications corresponding to the '772 patent have been filed, abandoned, withdrawn or rejected.
4. Foreign Counterparts to the '267 Patent

5.19 The foreign counterparts to the '267 patent are listed in Exhibit 18. No other foreign patents or patent applications corresponding to the '267 patent have been filed, abandoned, withdrawn or rejected.

C. U.S. Patent No. 7,743,767

1. Identification of the Patents and Ownership by ResMed


5.21 The inventors of the '767 patent, Anthony M. Ging, Saad Nasr, Philip R. Kwok, Rachael E. Moore, and Andrew M. Price, assigned to ResMed Ltd all rights, title, and interest in the invention ultimately disclosed and claimed in the '767 patent. See Exhibit 11. The '767 patent is valid, enforceable, and is currently in full force and effect. A certified copy of the '767 patent is attached as Exhibit 4.

5.22 Pursuant to Rule 210.12(c) of the Commission's Rules of Practice and Procedure, this Complaint is accompanied by Appendices D and K. Appendix D contains a certified copy and three additional copies of the prosecution history of the '767 patent; Appendix K contains four copies of each reference mentioned in that prosecution history.

2. Non-Technical Description of the Patented Invention
5.23 The ’767 patent generally discloses a respiratory mask assembly for delivering breathable air to a patient. See Exhibit 4, ’767 Patent, at Abstract. An embodiment of the invention is pictured in Figure 36:

![FIG. 36]

See id. at Fig. 36

5.24 The frame includes both a front surface, as well as a rear surface opposite the front surface and adapted to face the patient. See id. at Abstract. The rear surface of the frame includes inner and outer walls that define a channel between them. See id. A cushion is provided that sits between the frame and the patient’s face. See id. The cushion has a side wall that can be inserted into the channel of the frame. See id. Each of the cushion side wall and the channel have interlocking surfaces that engage each other in order to allow the cushion to be attached or detached from the frame. See id.

3. Foreign Counterparts to the ’767 Patent

5.25 The foreign counterparts to the ’767 patent are listed in Exhibit 15. No other foreign patents or patent applications corresponding to the ’767 patent have been filed, abandoned, withdrawn or rejected.

D. U.S. Patent No. 6,216,691
1. Identification of the Patent and Ownership by ResMed


5.27 The inventors of the '691 patent, Barton J. Kenyon, Alexander Virr, Marek T. Sapula, Philip R. Kwok, and Peter J.D. Wickham, assigned to ResMed Ltd all rights, title, and interest in the invention ultimately disclosed and claimed in the '691 patent. See Exhibit 12. The '691 patent is valid, enforceable, and is currently in full force and effect. A certified copy of the '691 patent is attached as Exhibit 5.

5.28 Pursuant to Rule 210.12(c) of the Commission's Rules of Practice and Procedure, this Complaint is accompanied by Appendices E and L. Appendix E contains four copies of the prosecution history of the '691 patent; Appendix L contains four copies of each reference mentioned in that prosecution history.

2. Non-Technical Description of the Patented Invention

5.29 The '691 patent generally discloses a mounting body for mounting a flow generator assembly inside an external housing. See Exhibit 5, '691 Patent, at Abstract. Figures 1 and 2 of the '691 patent depict one embodiment of this mounting body:

---

5 At the time of filing of the complaint, a certified copy of the file history of the '691 patent had been ordered. In accordance with Rule 210(a)(9)(i), a certified copy of the '691's file history will be filed with the Commission when received by Complainants.
See id. at Figs. 1 and 2.

5.30 The mounting body is made of a compliant material such as polyurethane foam, and is constructed in such a way that it can be attached to an external housing or case. See id. at Abstract. As noted previously, a flow generator generally consists of an electric motor driving a fan or turbine. The mounting body of the '691 patent has an indentation or recess of roughly the same size and shape of the flow generator. See id. A flow generator can be installed into this recess in the mounting body. See id. The flow generator installed in the mounting body can be contained in an external housing, and can be used to provide breathable air to a patient during CPAP treatment. See id.

3. Foreign Counterparts to the '691 Patent

5.31 The foreign counterparts to the '691 patent are listed in Exhibit 19. No other foreign patents or patent applications corresponding to the '691 patent have been filed, abandoned, withdrawn or rejected.

E. U.S. Patent Nos. 6,935,337 and 7,614,398

1. Identification of the Patents and Ownership by ResMed

5.33 The inventors of both the '337 and '398 patents, Alexander Virr, Ian M. Smith, Perry D. Lithgow, Richard L. Jones, and Andrew Cheung, assigned to ResMed Ltd all rights, title, and interest in the invention ultimately disclosed and claimed in both the '337 and '398 patents. See Exhibits 13 and 14. The '337 and '398 patents are valid, enforceable, and are currently in full force and effect. A certified copy of the '337 patent is attached as Exhibit 6, and a certified copy of the '398 patent is attached as Exhibit 7.

5.34 Pursuant to Rule 210.12(c) of the Commission's Rules of Practice and Procedure, this Complaint is accompanied by Appendices F, G, M, and N. Appendix F contains one certified copy and three additional copies of the prosecution history of the '337 patent; Appendix M contains four copies of each reference mentioned in that prosecution history. Appendix G contains one certified copy and three additional copies of the prosecution history of the '398 patent; Appendix N contains four copies of each reference mentioned in that prosecution history.

2. Non-Technical Description of the Patented Invention
5.35 The '337 and '398 patents generally disclose a humidifier for humidifying air in a CPAP system. See Exhibit 6, '337 Patent, at Abstract, and Exhibit 7, '398 patent, at Abstract. An embodiment of the invention is pictured in Figures 6 and 7:

![Image of humidifier diagram]

*See id. at Fig. 6.*

*See id. at Fig. 7*

5.36 The humidifier of the invention has a top cover attached to a base, with a seal between the two; a part of the base can be made of a heat conducting material. See Exhibit 7, '398 Patent, at Abstract. The base has a reservoir chamber within it to store a body of liquid. See Exhibit 6, '337 Patent, at Abstract. Air from a blower or flow generator enters the humidifier via an inlet port. See id. Air coming in through the inlet port is humidified by the liquid in the reservoir chamber, and subsequently exits the humidifier through an outlet port. See Exhibit 7, '398 Patent, at Abstract. Once the humidified air exits through the outlet port, it is delivered to the patient via a conduit. See Exhibit 6, '337 Patent, at Abstract. Additionally, the
reservoir chamber of the invention is constructed to prevent liquid in the chamber from backflowing into the inlet port when the humidifier is rotated from its normal position. See id.

3. Foreign Counterparts to the ’337 Patent

5.37 The foreign counterparts to the ’337 patent are listed in Exhibit 20. No other foreign patents or patent applications corresponding to the ’337 patent have been filed, abandoned, withdrawn or rejected.

4. Foreign Counterparts to the ’398 Patent

5.38 The foreign counterparts to the ’398 patent are listed in Exhibit 21. No other foreign patents or patent applications corresponding to the ’398 patent have been filed, abandoned, withdrawn or rejected.

VI. THE DOMESTIC INDUSTRY

6.1 A domestic industry exists as defined by 19 U.S.C. §§ 1337(a)(2)–(3) relating to ResMed’s significant investment in plant and equipment; significant employment of labor or capital; and substantial investment in exploitation of the patents, including a variety of technical support, field training and professional clinical education, customer support, and service and repair activities with respect to ResMed’s domestic industry sleep-disordered breathing treatment systems and components thereof. While a portion of the manufacturing of ResMed’s domestic industry products occurs outside of the United States, ResMed’s activities in the United States with respect to these products constitutes a domestic industry for purposes of Section 337. In addition, ResMed’s domestic industry products are protected by the one or more claims of each of the Asserted Patents.

A. Technical Prong

6.2 ResMed manufactures, assembles, and sells sleep-disordered breathing treatment systems and components thereof. As set forth in more detail herein, ResMed’s sleep-disordered
breathing treatment systems and components thereof incorporate the inventions claimed in one or more of the Asserted Patents.

6.3 The following components of ResMed SDB treatment systems are protected by the '772 patent: Quattro FX, Quattro FX For Her, Mirage Vista, Mirage Quattro, Mirage Micro, Mirage Liberty, and Mirage Activa LT. Photographs of these ResMed products are attached as Exhibits 22-27. Copies of the user manuals for these ResMed Products are attached as Exhibits 29-34. Claim charts demonstrating how representative ResMed products are protected by an exemplary claim of the '772 patent are attached as Exhibits 39, and 41-44.

6.4 The following components of ResMed SDB treatment systems are protected by the '267 patent: Quattro FX, Quattro FX For Her, Mirage Vista, Mirage Quattro, Mirage Micro, Mirage Liberty, and Mirage Activa LT. Photographs of these ResMed products are attached as Exhibits 22-27. Copies of the user manuals for these ResMed Products are attached as Exhibits 29-34. Claim charts demonstrating how representative ResMed products are protected by an exemplary claim of the '267 patent are attached as Exhibits 45, and 47-50.

6.5 The following components of ResMed SDB treatment systems are protected by the '587 patent: Quattro FX, Quattro FX For Her, Mirage Quattro. Photographs of these ResMed products are attached as Exhibits 25 and 27. Copies of the user manuals for these ResMed Products are attached as Exhibits 32 and 34. Claim charts demonstrating how these ResMed products are protected by an exemplary claim of the '587 patent are attached as Exhibit 37-38.

6.6 The following components of ResMed SDB treatment systems are protected by the '767 patent: Mirage Vista, Quattro FX, Quattro FX For Her, Mirage Micro. Photographs of these ResMed products are attached as Exhibits 24, 26, and 27. Copies of the user manuals for
these ResMed Products are attached as Exhibits 31, 33, and 34. A claim chart demonstrating how a representative ResMed product is protected by an exemplary claim of the '767 patent is attached as Exhibit 51.

6.7 The following components of ResMed SDB treatment systems are protected by the '691 patent: the S9 series of devices. Photographs of an S9 device are attached as Exhibit 28. A copy of the user manual for the S9 device is attached as Exhibit 35. A claim chart demonstrating how the S9 device is protected by an exemplary claim of the '691 patent is attached as Exhibit 53.

6.8 The following component of the ResMed SDB treatment systems is protected by the '337 patent: the H5i heated humidifier. Photographs of the H5i heated humidifier are attached as Exhibit 28. A copy of the user manual for the H5i is attached as Exhibit 35. A claim chart demonstrating how the H5i heated humidifier is protected by an exemplary claim of the '337 patent is attached as Exhibit 54.

6.9 The following component of the ResMed SDB treatment systems is protected by the '398 patent: the H5i heated humidifier. Photographs of the H5i heated humidifier are attached as Exhibit 28. A copy of the user manual for the H5i is attached as Exhibit 35. A claim chart demonstrating how the H5i heated humidifier is protected by an exemplary claim of the '398 patent is attached as Exhibit 55.

B. Economic Prong

6.10 ResMed conducts significant domestic industry activities in the United States relating to products protected by one or more claims of the Asserted Patents. These activities include the research and development and manufacturing of electronic motors (the key

---

6 The pictures of the S9 and the H5i are shown together in a single exhibit.
component in the ResMed flow generators contained in ResMed’s sleep-disordered breathing
treatment systems), the packaging of these systems, the education, training and sales of the sleep-
disordered breathing systems, and other activities designed to exploit the patents at issue such as
customer support, warranty and repair services, and clinical educational activities. ResMed’s
investment in plant and equipment, employment of labor and capital, and substantial investment
in the exploitation of the Asserted Patents and the investments in these activities is set forth in a
confidential declaration attached to this complaint. See Confidential Exhibit 56. A copy of
ResMed Inc.’s Form 10-K and Annual Report for the fiscal year ending June 30, 2010 is attached
as Exhibit 79.

6.11 ResMed has made and continues to make significant investment in facilities and
equipment in the United States dedicated to the research and development, manufacture,
assembly, product support, testing and quality management, and warranty and repair services for
products protected by the Asserted Patents. The plant facilities and equipment used in
connection with ResMed’s products are located in California and South Carolina. ResMed’s
investment in plant and equipment is set forth in Confidential Exhibit 56.

6.12 ResMed has employed and continues to employ a significant number of
employees in the above-mentioned facilities that devote substantial personnel-hours toward the
manufacture, assembly, customer and product support, testing and quality management, and
warranty and repair services for products protected by the Asserted Patents. Additionally,
ResMed employees conduct clinical education sessions to educate clinical professionals on the
use of products protected by the Asserted Patents. Confidential Exhibit 56 describes this labor
investment.
6.13 ResMed has invested and continues to invest significant capital in its domestic facilities toward customer and product support, testing and quality management, clinical education, and warranty and repair services for products protected by the Asserted Patents. Confidential Exhibit 56 describes the capital ResMed has expended towards these activities.

VII. UNLAWFUL AND UNFAIR ACTS OF PROPOSED RESPONDENTS

7.1 Upon information and belief, Proposed Respondents’ accused products directly infringe at least: claims 1, 5, 6, 11, 12, 18, 19, 20, 35 and 36 of the ’772 patent; claims 17, 21, 22, 23, 24, 29, 32, 33, 34, 35, 36 and 37 of the ’267 patent; claim 15 of the ’587 patent; claims 59, 60, 63, 72, 73, 74 and 75 of the ’767 patent; claims 1, 2, 4, 5, 17 and 28 of the ’691 patent; claims 1 and 20 of the ’337 patent; and claims 1, 2, 3, 4, 5, 6 and 7 of the ’398 patent. On information and belief, the accused products are manufactured, assembled, packaged, and/or tested overseas, specifically, at least in Taiwan. On information and belief, these same products are then imported into the United States, sold for importation into the United States, and/or sold after importation into the United States by Proposed Respondents. See Exhibit 81. Further discovery may reveal that Proposed Respondents infringe additional claims of the Asserted Patents.

A. Apex

7.2 On information and belief, Apex’s WiZARD 210 and WiZARD 220 infringe the asserted claims of the ’587 patent. Further discovery may reveal additional infringing Apex products and/or models. Photographs of a representative Apex WiZARD 210 and a representative WiZARD 220 are attached to this Complaint as Exhibit 57 and Exhibit 58, respectively. A copy of the user brochure for the representative WiZARD 210 and WiZARD 220 is attached to this Complaint as Exhibit 62. Claim charts demonstrating how the asserted
independent claims of the '587 patent are infringed by the representative accused products are attached as Exhibit 65 and Exhibit 66.

7.3 On information and belief, Apex's WiZARD 210 and WiZARD 220 infringe the asserted claims of the '772 patent. Further discovery may reveal additional infringing Apex products and/or models. Photographs of a representative Apex WiZARD 210 and a representative WiZARD 220 are attached to this Complaint as Exhibit 57 and Exhibit 58, respectively. A copy of the user brochure for the representative WiZARD 210 and WiZARD 220 is attached to this Complaint as Exhibit 62. Claim charts demonstrating how the asserted independent claims of the '772 patent are infringed by the representative accused products are attached as Exhibit 67 and Exhibit 68.

7.4 On information and belief, Apex's WiZARD 210 and WiZARD 220 infringe the asserted claims of the '267 patent. Further discovery may reveal additional infringing Apex products and/or models. Photographs of a representative Apex WiZARD 210 and a representative WiZARD 220 are attached to this Complaint as Exhibit 57 and Exhibit 58, respectively. A copy of the user brochure for the representative WiZARD 210 and WiZARD 220 is attached to this Complaint as Exhibit 62. Claim charts demonstrating how the asserted independent claims of the '267 patent are infringed by the representative accused products are attached as Exhibit 69 and Exhibit 70.

7.5 On information and belief, Apex's WiZARD 210 infringes the asserted claims of the '767 patent. Further discovery may reveal additional infringing Apex products and/or models. A photograph of a representative Apex WiZARD 210 is attached to this Complaint as Exhibit 57. A copy of the user brochure for the representative WiZARD 210 is attached to this
Complaint as Exhibit 62. Claim charts demonstrating how the asserted independent claims of the '767 patent are infringed by the representative accused product are attached as Exhibit 71.

7.6 On information and belief, Apex's XT Fit and iCH Auto infringe the asserted claims of the '691 patent. Further discovery may reveal additional infringing Apex products and/or models. Photographs of a representative Apex XT Fit and a representative iCH Auto are attached to this Complaint as Exhibit 59 and Exhibit 61, respectively. A copy of the user brochure for the representative XT Fit and a copy of the user brochure for the representative iCH Auto are attached to this Complaint as Exhibit 64 and Exhibit 63, respectively. Claim charts demonstrating how the asserted independent claims of the '691 patent are infringed by the representative accused products are attached as Exhibit 72 and Exhibit 73.

7.7 On information and belief, Apex's iCH Auto infringes the asserted claims of the '337 patent. Further discovery may reveal additional infringing Apex products and/or models. Photographs of a representative Apex iCH Auto are attached to this Complaint as Exhibit 61. A copy of the user brochure for the representative iCH Auto is attached to this Complaint as Exhibit 63. A claim chart demonstrating how the asserted independent claims of the '337 patent are infringed by the representative accused product is attached as Exhibit 74.

7.8 On information and belief, Apex's XT Humidifier infringes the asserted claims of the '398 patent. Further discovery may reveal additional infringing Apex products and/or models. Photographs of a representative Apex XT Humidifier are attached to this Complaint as Exhibit 60. A copy of the user brochure for the representative XT Humidifier is attached to this Complaint as Exhibit 64. A claim chart demonstrating how the asserted independent claims of the '398 patent are infringed by the representative accused product is attached as Exhibit 75.

7 Photos of the XT Fit show the unit complimentarily attached to the XT Humidifier.
8 Photos of the XT Humidifier show the unit complimentarily attached to the XT Fit.
B. Drive

7.9 On information and belief, Drive imports the Apex Wizard 210 and the Apex Wizard 220 and rebrands them as the Freedom 210 and Freedom 220 respectively. For example, attached as Exhibit 83 are photographs of a Drive Freedom 210 in its original packaging that ResMed purchased. As can be seen in the photographs, the Freedom 210 is branded with Drive's brand name:

See Exhibit 83, Photographs of Drive Freedom 210 (annotated).

7.10 However, the nasal cushion attached to the mask inside the packaging bears what appears to be a label reading "WiZARD 210":

See id. (annotated).

7.11 Additionally, extra replacement nasal cushions provided in the Freedom 210 box also appear to bear a label reading “WiZARD 210”: 
7.12 Therefore, Drive’s Freedom 210 infringes the asserted claims of the '267, '587, '767, and '772 patents for the reasons described previously with respect to the Apex Wizard 210, and in the associated claim charts. Drive’s Freedom 220 infringes the asserted claims of the '267, '587, and '772 patents for the reasons described previously with respect to the Apex Wizard 220, and in the associated claim charts. Further discovery may reveal additional infringing Drive products and/or models. Photographs of a representative Drive Freedom 210 and a representative Drive Freedom 220 are attached to this Complaint as Exhibit 76 and Exhibit 77, respectively. A copy of the catalog page from Drive showing the Drive Freedom 210 and 220 is attached to this complaint as Exhibit 80.

VIII. SPECIFIC INSTANCES OF UNFAIR IMPORTATION AND SALE
8.1 On information and belief, Proposed Respondents, and/or others on their behalf, manufacture the accused products at least in Taiwan, and then import them into the United States, sell them for importation into the United States and/or sell them after importation into the United States. On information and belief, Apex offers for sale its infringing articles both directly to customers in the United States, and through intermediary suppliers that sell products in the United States, such as Drive.

8.2 A review of import information downloaded from http://www.zepol.com\(^9\) shows that both Apex and Drive have imported sleep-disordered breathing treatment systems and/or components thereof into the United States. See Exhibit 81 (demonstrating imports of continuous positive airway pressure systems and/or masks). On information and belief, Apex currently imports and sells only two CPAP mask products in the United States: the accused WiZARD 210 and WiZARD 220. The data from zepol.com indicates shipments of goods described as, for example, “mask, Continuous Positive Airway Pressure” and “cpap Full Face Mask.” Therefore, though the import data does not specify the brand names (i.e. WiZARD 210 or 220), the import data in all likelihood includes imports of the Apex WiZARD 210 and 220 because those are believed to be currently the only Apex CPAP masks imported or sold in the United States.

8.3 In addition to the above, ResMed has obtained representative accused products of both Apex and Drive in the United States. Labels on the device and/or product packaging indicate that the accused products were manufactured in Taiwan. Attached as Exhibit 78 are photographs of the product packaging for the Apex WiZARD 210 and WiZARD 220, reflecting

\(^{9}\) Zepol’s “TradeIQ” database provides information about imports and exports based on U.S. Customs: “TradeIQ™ Import data is from the Automated Manifest System (AMS) of U.S. Customs. Shipment details go back to 2003 and are available within 3 to 10 days of shipment arrival.” See http://www.zepol.com/Products/TradeIQ/TradeIQ.aspx (last accessed March 17, 2013).
that they were made in Taiwan. Attached as Exhibit 82 are photographs of the product packaging for the Drive Freedom 210 reflecting that it was manufactured in Taiwan.

8.4 The accused products are believed to fall within at least the following classifications of the Harmonized Tariff Schedules of the United States: 9019.20.00, and 9817.00.96. This classification is intended for illustrative purposes only and is not intended to restrict the scope or type of accused product.

IX. LICENSEES

9.1 ResMed has licensed one or more of the Asserted Patents. Pursuant to Commission Rule 210.12, ResMed states that for all of the Asserted Patents ResMed Ltd has granted ResMed Inc. an exclusive license with the right to sublicense. ResMed Inc. has granted an exclusive license to all the asserted patents to ResMed Corp. Copies of these licenses can be found in Confidential Exhibit 89. A list of all licensees can be found in Confidential Exhibit 90.

X. RELATED LITIGATION

10.1 On the same day ResMed is filing this Complaint, ResMed is filing suit in the U.S. District Court for the Central District of California, where Apex’s offices are located, asserting that Proposed Respondents infringe the patents asserted here: the ’587, ’772, ’767, ’267,’691, ’337, and ’398 patents. There has been no other foreign or domestic court or agency litigation involving any of the Asserted Patents, or the subject matter thereof.

XI. REQUESTED RELIEF

11.1 WHEREFORE, by reason of the foregoing, ResMed requests that the United States International Trade Commission:

(a) Institute an immediate Investigation, pursuant to Section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. § 1337, with respect to violations of Section 337 based on the proposed Respondent’s unlawful importation into the United States, sale for
importation into the United States, and/or sale within the United States after importation of certain sleep-disordered breathing treatment systems and components thereof, which infringe one or more claims of United States Patent Nos. 7,159,587; 7,487,772; 7,997,267; 7,743,767; 6,216,691; 6,935,337; and 7,614,398;

(b) Schedule and conduct a hearing on the unlawful acts and, following the hearing, determine that there has been a violation of Section 337;

(c) Issue a permanent exclusion order, pursuant to Section 337(d) of the Tariff Act of 1930, as amended, excluding from entry into the United States all of the proposed Respondent's sleep-disordered breathing treatment systems and components thereof which infringe one or more claims of United States Patent Nos. 7,159,587; 7,487,772; 7,997,267; 7,743,767; 6,216,691; 6,935,337; or 7,614,398;

(d) Issue a permanent cease and desist order, pursuant to Section 337(f) of the Tariff Act of 1930, as amended, directing the proposed Respondents to cease and desist from the importation, marketing, advertising, demonstrating, warehousing inventory for distribution, sale and use of certain sleep-disordered breathing treatment systems and components thereof that infringe one or more claims of United States Patent Nos. 7,159,587; 7,487,772; 7,997,267; 7,743,767; 6,216,691; 6,935,337; or 7,614,398; and

(e) Grant such other and further relief as the Commission deems just and proper based on the facts determined by the Investigation and the authority of the Commission.
Respectfully submitted,

FISH & RICHARDSON P.C.

Dated: March 28, 2013

By: 

[Signature]

Roger Denning
Scott Penner
FISH & RICHARDSON P.C.
12390 El Camino Real
San Diego, CA 92130
Telephone: (858)-678-5070
Fax: (858)-678-5099

Thomas “Monty” Fusco
W. Peter Guarnieri
FISH & RICHARDSON P.C.
1425 K Street, N.W., 11th Floor
Washington, D.C. 20005
Telephone: (202) 783-5070
Facsimile: (202) 783-2331

Frank E. Scherkenbach
FISH & RICHARDSON P.C.
One Marina Park Drive
Boston, MA 02210-1878
Telephone: (617)-542-5070
Fax: (617)-542-8906

Michael J. Kane
FISH & RICHARDSON P.C.
3200 RBC Plaza
60 South Sixth Street
Minneapolis, MN 55402
Telephone: (612)-335-5070
Fax: (612)-288-9696

Counsel for Complainants ResMed Ltd,
ResMed Inc., and ResMed Corp.